BNP Paribas Purchases 243 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BNP Paribas boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,733 shares of the biopharmaceutical company’s stock after acquiring an additional 243 shares during the period. BNP Paribas’ holdings in Regeneron Pharmaceuticals were worth $1,822,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Brown Lisle Cummings Inc. raised its position in Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the last quarter. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Adirondack Trust Co. raised its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. lifted its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Finally, Western Financial Corp CA boosted its holdings in Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after acquiring an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of several research analyst reports. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Stock Up 0.5 %

Regeneron Pharmaceuticals stock opened at $753.03 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The stock has a fifty day simple moving average of $929.13 and a two-hundred day simple moving average of $1,024.43. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market cap of $82.75 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 2.89 and a beta of 0.15.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.